Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward?
Standard
Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward? / Rottner, Laura; Mathew, Shibu; Reissmann, Bruno; Warneke, Laura; Martin, Isabell; Lemes, Christine; Maurer, Tilman; Wohlmuth, Peter; Ouyang, Feifan; Kuck, Karl-Heinz; Metzner, Andreas; Rillig, Andreas.
in: CLIN CARDIOL, Jahrgang 43, Nr. 4, 01.04.2020, S. 394-400.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward?
AU - Rottner, Laura
AU - Mathew, Shibu
AU - Reissmann, Bruno
AU - Warneke, Laura
AU - Martin, Isabell
AU - Lemes, Christine
AU - Maurer, Tilman
AU - Wohlmuth, Peter
AU - Ouyang, Feifan
AU - Kuck, Karl-Heinz
AU - Metzner, Andreas
AU - Rillig, Andreas
N1 - © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - BACKGROUND: The second-generation cryoballoon (CB2) is widely used for pulmonary vein (PV) isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). Recently, the novel fourth-generation CB (CB-Advance PRO) was introduced, incorporating a shortened catheter tip.HYPOTHESIS: The aim of this study was to evaluate the feasibility and acute efficacy of PVI using the CB-Advance PRO.METHODS: A total of 200 consecutive patients were analyzed. Hundred patients who underwent PVI due to symptomatic, drug-refractory AF were treated with the CB-Advance PRO (group I) and were included into this multicenter analysis. A group of 100 patients were treated with the CB2 and acted as controls (group II).RESULTS: In total, 739 of 739 PVs (100%) were successfully isolated. There was a nonsignificant trend in the incidence of online registration of PV signals between both groups (group I: 77.9% vs group II: 71.4%, P = .09). Median time to PVI (time to isolation [TTI]) and mean total freezing time were significantly shorter when using the CB-Advance PRO (group I: 33 [23, 50] vs group II: 40 [26, 60] seconds and group I: 166 ± 29 vs group II: 183 ± 38 seconds, P < .01). In three of 100 (3%) patients of group I and one of 100 (1%) patients of group II, a transient phrenic nerve palsy occurred (P = .62).CONCLUSION: The use of the novel CB-Advance PRO is feasible and associated with a significant reduction in mean TTI and mean total freezing time as compared to the CB2.
AB - BACKGROUND: The second-generation cryoballoon (CB2) is widely used for pulmonary vein (PV) isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). Recently, the novel fourth-generation CB (CB-Advance PRO) was introduced, incorporating a shortened catheter tip.HYPOTHESIS: The aim of this study was to evaluate the feasibility and acute efficacy of PVI using the CB-Advance PRO.METHODS: A total of 200 consecutive patients were analyzed. Hundred patients who underwent PVI due to symptomatic, drug-refractory AF were treated with the CB-Advance PRO (group I) and were included into this multicenter analysis. A group of 100 patients were treated with the CB2 and acted as controls (group II).RESULTS: In total, 739 of 739 PVs (100%) were successfully isolated. There was a nonsignificant trend in the incidence of online registration of PV signals between both groups (group I: 77.9% vs group II: 71.4%, P = .09). Median time to PVI (time to isolation [TTI]) and mean total freezing time were significantly shorter when using the CB-Advance PRO (group I: 33 [23, 50] vs group II: 40 [26, 60] seconds and group I: 166 ± 29 vs group II: 183 ± 38 seconds, P < .01). In three of 100 (3%) patients of group I and one of 100 (1%) patients of group II, a transient phrenic nerve palsy occurred (P = .62).CONCLUSION: The use of the novel CB-Advance PRO is feasible and associated with a significant reduction in mean TTI and mean total freezing time as compared to the CB2.
KW - Action Potentials
KW - Aged
KW - Atrial Fibrillation/diagnosis
KW - Cardiac Catheters
KW - Catheter Ablation/adverse effects
KW - Cryosurgery/adverse effects
KW - Equipment Design
KW - Feasibility Studies
KW - Female
KW - Germany
KW - Heart Rate
KW - Humans
KW - Male
KW - Middle Aged
KW - Operative Time
KW - Postoperative Complications/etiology
KW - Pulmonary Veins/physiopathology
KW - Retrospective Studies
KW - Time Factors
KW - Treatment Outcome
U2 - 10.1002/clc.23328
DO - 10.1002/clc.23328
M3 - SCORING: Journal article
C2 - 32097501
VL - 43
SP - 394
EP - 400
JO - CLIN CARDIOL
JF - CLIN CARDIOL
SN - 0160-9289
IS - 4
ER -